Your fact-checks will appear here
Neurological disorder associated with COVID-19 vaccines and SARS-CoV-2 infection
The currently recommends a single dose of an for all adults age 75 years and older, and for adults ages 50–74 who are at increased risk for ; earlier guidance and professional groups also noted recomm...
, the recombinant zoster vaccine introduced as a more effective successor to Zostavax, has provoked debate largely centered on rare but serious neurologic events, higher reactogenicity than older vacc...
Post-licensure monitoring of has flagged a handful of rare but serious adverse-event signals — notably (GBS), and thrombocytopenia, atrial fibrillation/cardiac events, in pregnancy, and a safety signa...
Respiratory syncytial virus (RSV) vaccines are new prevention tools designed to reduce severe RSV illness in infants, pregnant people, and older adults; regulatory rollouts since 2022 have produced ma...
, in absolute numbers reported to surveillance systems and compensation programs, is real but uncommon relative to the hundreds of millions of vaccine doses administered; most reports do not establish...
Large population studies and systematic reviews show that carries a substantially higher and broader burden of neurological disease than licensed spike‑based COVID‑19 vaccines, while vaccines are link...
Large-scale population studies and specialist reviews conclude that clinically significant delayed autoimmune or neurological conditions after are uncommon and, for most syndromes, no causal link has ...